The American Red Cross Relieves VDI Printing Pains with UniPrint Infinity
Ahead of their appearance at the VMworld US trade show in Las Vegas, Print Virtualization software provider UniPrint.net Corp announced today the release of their latest case study: The American Red Cross (ARC). With a national network of more than 300 chapters, The American Red Cross is one of the world’s premier charitable organizations made up of workers and volunteers providing humanitarian relief both in the United States and abroad.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170824005757/en/
The Challenge
The ARC’s IT infrastructure includes more than 20,000 employees and 300,000 volunteers in offices, remote locations, connecting from home, or in the field in disaster zones. In 2015, their End Use Technologies Solutions (EUTS) team began their search for a virtual workspace solution that would give their users access to applications, data, and resources from any location. Immediately, printing was identified as an issue, both due to driver incompatibility being common in VDI environments, and due to the tediousness of Group Policies for printer mapping with so many remote locations and devices.
They were also looking to eliminate hardware and consolidate remote site resources back to the data center, which posed potential bandwidth issues. Additionally, the EUTS team intended on instituting a BYOD (bring-your-own-device) model which would also require a stable print management solution.
The Solution
With their implementation of UniPrint Infinity™ The ARC was able to solve all of their printing challenges with one streamlined solution. The patented PDF-based Universal Printer Driver (UPD) solved the issue of printer driver incompatibility and eliminated the need for repeated and frequent vendor driver updates. Printer mapping issues were also solved with the PrintPAL utility, which allows administrators to implement broad printing policies with only a few clicks.
There was also the added benefit of reduced call volume to The ARC’s third-party service desk. Adam Flowers, Lead Solutions Architect, remarked:
“There was a reduction in helpdesk calls for printing related issues as we made improvements to our environment with UniPrint […] UniPrint saved us lots of time and headaches, and it really made our techs available to deal with higher priority issues.”
Other benefits included the flexibility of BYOD printing, as well as a reduction in bandwidth usage (and therefore a reduction in cost). UniPrint Infinity has not only helped The American Red Cross funnel more resources back into the community, but also helped staff spend less time on printing and more time focusing on making the world a better place.
“The UniPrint Infinity™ suite allows us to adapt to whatever situation our people may be in,” said Flowers. “There’s nothing we’ve been asked to do that UniPrint can’t handle.”
Key Benefits
- Universal Printer Driver (UPD) solves incompatibility issues and reduces helpdesk calls
- PrintPAL technology eliminates the need for mapping through Group Policies
- Reduces overhead cost through printer server consolidation
- High Availability (HA) module provides enterprise wide redundancy and fault tolerance
- Resolves bandwidth issues using PDF compression to compress and encrypt print jobs
- Provides local and remote users with seamless, stable, and secure printing from any device to the nearest available printer
To learn more, check out our video interview with Adam Flowers on how UniPrint Infinity transformed American Red Cross’ IT workflow, and don’t forget to stop by Booth 1724 at VMworld US in Las Vegas Aug. 27-31 to meet the UniPrint team!
About UniPrint.net Corp
UniPrint.net Corp. is an innovative leader in printing virtualization. Their patented PDF-based software, UniPrint Infinity™, is the industry’s first truly secure enterprise printing solution for any computing environment. UniPrint Infinity replaces all manufacturer printer drivers with a single Universal Printer Driver (UPD) to promote faster, more efficient printing. Both UniPrint™ and UniPrint Infinity™ are the trademarks of UniPrint.net. All other trademarks and registered trademarks are properties of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170824005757/en/
Contact information
UniPrint.net Corp.
Kate Bradford, 416-503-9800 x8258
Marketing
Specialist
kate.bradford@uniprint.net
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 202525.4.2025 15:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that the Company will present new early-stage data from its oncology portfolio at the American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL, from April 25–30. “At AACR we will be presenting data from early-stage programs across our oncology portfolio, including for patients with myeloproliferative neoplasms, ovarian cancer and other solid tumors,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These data will guide our approach as we advance our pipeline and seek to transform the treatment landscape for patients with cancer and myeloproliferative neoplasms.” Abstracts accepted for presentation at AACR include: Mini Symposium INCB177054 INCB177054: A Novel, Potent, Orally Bioavailable DGKα/ζ Dual Inhibitor Enhances T-Cell Function and Demonstrates Potent Antitumor Activity (Session Title: Novel Antitumor Agents. April 28, 4:50 p.m. – 5:05 p.m. ET (3:50 p.m. – 4:05 p.m. CT). Abstract #
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom